Deerfield Management (US Rights for Toprol-XL) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

Deerfield Management (US Rights for Toprol-XL) General Information

Description

Portfolio of distribution rights for a beta-blocker medicine. The portfolio consists of U.S. distribution rights for the branded and authorized generic drug designed for the treatment of hypertension (high blood pressure), angina (chest pain) and heart failure.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 2 Kingdom Street
  • London W2 6BD
  • England, United Kingdom
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Melinta Therapeutics
Corporate Office
  • 2 Kingdom Street
  • London W2 6BD
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Deerfield Management (US Rights for Toprol-XL) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Deerfield Management (US Rights for Toprol-XL)‘s full profile, request access.

Request a free trial

Deerfield Management (US Rights for Toprol-XL) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Deerfield Management (US Rights for Toprol-XL)‘s full profile, request access.

Request a free trial

Deerfield Management (US Rights for Toprol-XL) FAQs

  • Where is Deerfield Management (US Rights for Toprol-XL) headquartered?

    Deerfield Management (US Rights for Toprol-XL) is headquartered in London, United Kingdom.

  • What industry is Deerfield Management (US Rights for Toprol-XL) in?

    Deerfield Management (US Rights for Toprol-XL)’s primary industry is Buildings and Property.

  • Is Deerfield Management (US Rights for Toprol-XL) a private or public company?

    Deerfield Management (US Rights for Toprol-XL) is a Private company.

  • What is Deerfield Management (US Rights for Toprol-XL)’s current revenue?

    The current revenue for Deerfield Management (US Rights for Toprol-XL) is .

  • Who are Deerfield Management (US Rights for Toprol-XL)’s investors?

    Aralez Pharmaceuticals, AstraZeneca, and Deerfield Management have invested in Deerfield Management (US Rights for Toprol-XL).

  • When was Deerfield Management (US Rights for Toprol-XL) acquired?

    Deerfield Management (US Rights for Toprol-XL) was acquired on 06-Apr-2022.

  • Who acquired Deerfield Management (US Rights for Toprol-XL)?

    Deerfield Management (US Rights for Toprol-XL) was acquired by Melinta Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »